CELGENE REPORTS REVLIMID CANCER STUDY RESULTS

Celgene has announced updated clinical data from two Phase III pivotal studies evaluating Revlimid (lenalidomide) plus dexamethasone in previously treated multiple myeloma patients.

The updated clinical data from the international trial demonstrated that the combination of Revlimid plus dexamethasone led to a statistically significant improvement in median time to disease progression. The updated clinical data from the North American trialreported that the combination of REVLIMID plus dexamethasone led to a statistically significant improvement in overall survival in addition to a statistically significant improvement in median time to disease progression.